Brain Edema - Pipeline Review, H2 2016

  • ID: 3984502
  • Report
  • 40 pages
  • Global Markets Direct
1 of 5
Brain Edema - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Brain Edema - Pipeline Review, H2 2016, provides an overview of the Brain Edema (Central Nervous System) pipeline landscape.

Brain swelling is enlargement of the brain due to excessive fluid collection in the chambers, or ventricles, of the brain or the accumulation of fluid within the brain tissue itself. Cause of brain swelling includes traumatic brain injury (tbi), ischemic stroke, hemorrhages, tumors and infections (toxoplasmosis, meningitis, subdural empyema). Symptoms include headache, neck pain or stiffness, nausea or vomiting, dizziness, irregular breathing, vision loss or changes, memory loss, inability to walk, difficulty speaking, stupor, seizures and loss of consciousness.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Brain Edema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Brain Edema (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Brain Edema (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Brain Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Brain Edema.

Brain Edema (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Brain Edema (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Brain Edema (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Brain Edema (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Brain Edema (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Brain Edema (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Brain Edema (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Brain Edema (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Brain Edema Overview

Therapeutics Development

Pipeline Products for Brain Edema - Overview

Pipeline Products for Brain Edema - Comparative Analysis

Brain Edema - Therapeutics under Development by Companies

Brain Edema - Therapeutics under Investigation by Universities/Institutes

Brain Edema - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Brain Edema - Products under Development by Companies

Brain Edema - Products under Investigation by Universities/Institutes

Brain Edema - Companies Involved in Therapeutics Development

FibroGen Inc

Pharmazz Inc

Remedy Pharmaceuticals Inc

Brain Edema - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-4497 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glyburide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMZ-2123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Aquaporin-4 for Brain Edema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Brain Edema - Dormant Projects

Brain Edema - Product Development Milestones

Featured News & Press Releases

Jun 08, 2016: Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA

Apr 11, 2016: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting

Apr 06, 2016: Remedy Pharmaceuticals Issues First Quarter 2016 Report

Mar 04, 2016: Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema

Feb 22, 2016: Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA Presented at International Stroke Conference

Feb 08, 2016: Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA for CNS-Related Edema at ISC 2016

Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Edema, H2 2016

Number of Products under Development for Brain Edema - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Brain Edema - Pipeline by FibroGen Inc, H2 2016

Brain Edema - Pipeline by Pharmazz Inc, H2 2016

Brain Edema - Pipeline by Remedy Pharmaceuticals Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Brain Edema - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Brain Edema, H2 2016

Number of Products under Development for Brain Edema - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • FibroGen Inc
  • Pharmazz Inc
  • Remedy Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll